Health score, price, valuation, risk signals, and key metrics at a glance.
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Grade capped at D — Interest coverage below 1× (-16.9x) — earnings cannot cover interest. Strongest: Growth (19/25); weakest: Profitability (5/25).
Today's multiple positioned against its own trailing range — a visual premium/discount check.
Currently above its 5-quarter median.
Currently below its 20-quarter median.
Data-driven signals worth keeping an eye on across the last 8 quarters
The company posted negative operating margins in recent quarters — core operations are unprofitable.
Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.
as of June 2026
Revenue, EBITDA, operating income, net income, EPS, and shares
Gross, EBITDA, operating, and net margin trends
P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield
Total assets, cash, debt, book value, and leverage
Operating cash flow, free cash flow, FCF margin, and earnings quality
Currently below its 13-quarter median.
Debt-to-equity has risen 66.1% recently — increasing financial risk even if the current ratio is manageable.
The last 8 consecutive quarters had negative FCF — the company is burning cash and may need external funding.
